Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
Manolo D’Arcangelo,1,2 Federico Cappuzzo2 1Cancer Center, University of Colorado, Aurora (CO), USA; 2Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4b23c5be47f34ac981950e6910814146 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Manolo D’Arcangelo,1,2 Federico Cappuzzo2 1Cancer Center, University of Colorado, Aurora (CO), USA; 2Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC. Keywords: non-small cell lung cancer, MET, hepatocyte growth factor, ficlatuzumab, AV-299 |
|---|